<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0909245884
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ROCLANDA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LATANOPROST,NETARSUDIL MESYLATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50,200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µ/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ocular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Aerie Pharmaceuticals Ireland Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Aerie Pharmaceuticals Ireland Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1022]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Al Hamaed medical company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Santen Oy
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Roclanda contains the active substances latanoprost and netarsudil. Latanoprost belongs to a group of medicines known as prostaglandin analogues. Netarsudil belongs to a group of medicines called Rho kinase inhibitors. They work in different ways to reduce the amount of fluid, and so lower the pressure, inside the eye.</p><p>&nbsp;</p><p>Roclanda is used to lower pressure in the eyes in adults who have an eye condition known as glaucoma or who have raised pressure in their eyes. If the pressure in the eye is too high, it can damage your sight.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Roclanda</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to latanoprost or netarsudil or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p><strong>Take special care with Roclanda</strong></p><p>Talk to your doctor or pharmacist before using Roclanda if you think any of the following applies to you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from dry eyes;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe asthma or asthma that is not well controlled;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have suffered or are currently suffering from a viral infection of the eye caused by the herpes simplex virus.</p><p>&nbsp;</p><p>Do not use Roclanda more than once a day, as you may experience more side effects.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Roclanda should not be used in children and adolescents under 18 years of age as it is not known if it is safe or effective in this age group.</p><p>&nbsp;</p><p><strong>Using other medicines, herbal or dietary supplements</strong></p><p>Roclanda may interact with other medicines. Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines, especially any that contain another prostaglandin analogue like latanoprost.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Do not use Roclanda if you are pregnant.</p><p>&nbsp;</p><p>Driving and using machines</p><p>You may find that your vision is blurred or abnormal just after using Roclanda. Do not drive or use machines until your vision has cleared.</p><p>&nbsp;</p><p>Roclanda contains benzalkonium chloride</p><p>This medicine contains benzalkonium chloride which may be absorbed by soft contact lenses and change the colour of the contact lenses. You should remove contact lenses before using this medicine and not put them back before 15 minutes has passed.</p><p>&nbsp;</p><p>Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye). If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Only use Roclanda for your eyes (ocular use).</p><p>&nbsp;</p><p>The recommended dose is one drop in the affected eye once a day in the evening. Use the medicine at around the same time each day. Do not use it more than once a day.</p><p>&nbsp;</p><p>How to use</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image16.png" o:spid="_x0000_s1026" type="#_x0000_t75"
  alt="PIL ILLUSTRATION FINAL_HEAVY_M01" style='position:absolute;
  margin-left:73.5pt;margin-top:15.3pt;width:105.6pt;height:105.6pt;z-index:1840;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image001.png"
   o:title="PIL ILLUSTRATION FINAL_HEAVY_M01"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="141" height="141" alt="PIL ILLUSTRATION FINAL_HEAVY_M01" src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image002.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash your hands before you start.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not touch the dropper tip with your fingers when opening or closing the bottle. It could infect the eye drops.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Twist off the bottle cap, and lie the cap on a clean surface on its side. Continue to hold the bottle, ensuring that the tip doesn&rsquo;t come into contact with anything.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the bottle, pointing down, between your thumb and fingers.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tilt your head back.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pull down your lower eyelid with a clean finger to form a &lsquo;pocket&rsquo; between the eyelid and your eye. The drop will go in here.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bring the dropper tip close to the eye. Do this in front of a mirror if it helps.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not touch your eye, eyelid, surrounding areas or other surfaces with the dropper tip. It could infect the eye drops.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently squeeze the bottle to release one drop of Roclanda into your eye.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Only put one drop into your eye each time. If a drop misses your eye, try again.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press a finger against the corner of the eye by the nose. Hold for 1 minute whilst keeping the eye closed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you need to use the drops in both eyes</strong>, repeat the steps for your other eye while you have the bottle open.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put back the bottle cap to close the bottle.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put the bottle back into the carton to protect the drops from light until you need to use the drops again.</p><p>&nbsp;</p><p><strong>If you are using other eye drops</strong>, wait at least five minutes after using them and then use Roclanda. If you are using an eye ointment, it should be used last.</p><p>&nbsp;</p><p>If you use more Roclanda than you should</p><p>Rinse your eye with warm water. Do not put in any more drops until it is time for your next regular dose.</p><p>&nbsp;</p><p>If you forget to use Roclanda</p><p>Continue with the next dose as planned. Do not use a double dose to make up for a forgotten dose. Do not use more than one drop in the affected eye once a day.</p><p>&nbsp;</p><p>If you stop using Roclanda</p><p>Do not stop using Roclanda without first speaking to your doctor. If you stop using Roclanda the pressure in your eye will not be controlled which could lead to loss of sight.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The following side effects have been observed with Roclanda and other medicines containing latanoprost and netarsudil alone:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common (may affect more than 1 in 10 people)</p><p>o&nbsp;&nbsp;&nbsp; <em>Effects in the eye:</em></p><p>&sect;&nbsp; Eye redness; fine deposits on the front of the eye and pain where the drops have been put in; a gradual increase in the amount of brown pigment in the coloured part of the eye (the iris) leading to altered eye colour; a gradual increase in the colour (darkening), length, thickness and number of your eye lashes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common (may affect up to 1 in 10 people)</p><p>o&nbsp;&nbsp;&nbsp; <em>Effects in the eye:</em></p><p>&sect;&nbsp; Infection or inflammation of the eye; dryness of the eye or small breaks in the film of liquid on the surface of the eye; eye discharge; itchy eyelids; clouding of the eye and slight decrease in vision; eye pain; feeling of grittiness or having something in the eye; general eye redness shortly after drops are put in; spots or patches of eye redness; conjunctivitis (eye inflammation or prominent blood vessels) caused by an allergic reaction; watery eyes; swelling around the eye; eyelid crusting; blurred vision;</p><p>o&nbsp;&nbsp;&nbsp; <em>General side effects</em></p><p>&sect;&nbsp; redness or itching of the skin on your face</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon (may affect up to 1 in 100 people)</p><p>o&nbsp;&nbsp;&nbsp; <em>Effects in the eye:</em></p><p>&sect;&nbsp; Increased fluid pressure inside the eye; inflammation of the coloured part of the eye (the iris); bulging of iris; increased wrinkling of the clear layer over the eye where it meets with the lower eyelid; blindness; blurred, double or halo vision; blocked tear duct; small colored spots on the eye surface; eyelid dryness; eye dryness caused by inflammation of the glands of the eyelids; eye allergy; shiny/glassy eyes; tiredness; numbness or burning in the eye; abnormal turning outward of the lower eyelid; loss of eyelashes; eye disease related to diabetes; increased sensitivity to light; discoloration of eyelid skin</p><p>o&nbsp;&nbsp;&nbsp; <em>Side effects in other parts of the body</em></p><p>&sect;&nbsp; Blocked nose; nosebleed; nasal discomfort and pain; headache; dizziness; being sick (vomiting); redness or itching of the skin; dry skin; thickening of the skin; muscle pain or spasm or weakness; joint pain; jaw pain; picking at your skin; inflammation of the cartilage; chest pain (angina); awareness of heart beat (palpitations); asthma; shortness of breath (dyspnoea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare (may affect up to 1 in 1000 people)</p><p>o&nbsp;&nbsp;&nbsp; <em>Effects in the eye:</em></p><p>&sect;&nbsp; Swelling or scratching with damage to the surface of the eye; swelling around the eye (periorbital oedema); eyelashes growing in the wrong direction or an extra row of eyelashes; scarring of the surface of the eye; fluid filled area within the coloured part of the eye (iris cyst); skin reactions on the eyelids; darkening of the skin of the eyelids; viral infection of the eye caused by herpes simplex virus (HSV).</p><p>o&nbsp;&nbsp;&nbsp; <em>Side effects in other parts of the body</em></p><p>&sect;&nbsp; Worsening of asthma; severe itching of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rare (may affect up to 1 in 10,000 people)</p><p>o&nbsp;&nbsp;&nbsp; <em>Effects in the eye:</em></p><p>&sect;&nbsp; Sunken eye appearance (eye sulcus deepening).</p><p>o&nbsp;&nbsp;&nbsp; <em>Side effects in other parts of the body</em></p><p>&sect;&nbsp; Worsening of angina in patients who also have heart disease</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the bottle and the carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Unopened bottle: Store in a refrigerator (2 &deg;C to 8 &deg;C).</p><p>After opening the bottle: Do not store above 25 &deg;C.</p><p>&nbsp;</p><p>Store in the original carton in order to protect from light.</p><p>&nbsp;</p><p>Throw away the bottle 4 weeks after first opening to prevent infections and use a new bottle.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp; The active substances are latanoprost and netarsudil. Each ml of solution contains 50 micrograms latanoprost and 200 micrograms netarsudil (as mesylate).</p><p>-&nbsp;&nbsp;&nbsp; The other excipients are benzalkonium chloride (see section 2 under &lsquo;Roclanda contains benzalkonium chloride&rsquo;), mannitol, boric acid, sodium hydroxide (for pH adjustment) and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Eye drops, solution. 
Roclanda is a clear, liquid eye drop solution in a plastic bottle. Each bottle contains 2.5 ml of the medicine and each pack contains one bottle with a screw-cap.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p>Santen Oy</p><p>Niittyhaankatu 20, 33720 Tampere, Finland</p><p>&nbsp;</p><p>Manufacturer</p><p>Aerie Pharmaceuticals Ireland, Limited</p><p>Athlone Business and Technology Park, Dublin Road, Garrycastle, Athlone, Co Westmeath, N37 DW40, Ireland</p><p>&nbsp;</p><p><strong>Manufacturer responsible for batch release</strong></p><p>Santen&nbsp;Oy</p><p>Kelloportinkatu 1, 33100 Tampere, Finland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised 05/2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي روكلاندا المادتين الفعالتين لاتانوبروست ونيتارسوديل. ينتمي لاتانوبروست إلى مجموعة الأدوية المسماة نظائر البروستاجلاندين. ينتمي نيتارسوديل إلى مجموعة الأدوية المسماة مثبطات رو كيناز. تعمل المادتان بطرق مختلفة لتقليل كمية السائل؛ وبهذا ينخفض الضغط داخل العين.</p><p>&nbsp;</p><p dir="RTL">يستخدم روكلاندا لخفض ضغط عين البالغين المصابين بمشكلة في العين تسمى المياه الزرقاء أو من يعانون من ارتفاع الضغط داخل أعينهم. إن ارتفع الضغط داخل العين بشدة، فيمكن أن تؤدي إلى تلف بصرك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستعمل روكلاندا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من حساسية تجاه دواء لاتانوبروست أو نيتارسوديل أو أي من المكونات الأخرى لهذا الدواء (المدرجة في الجزء 6).</p><p dir="RTL">-<br />&nbsp;</p><p dir="RTL"><strong>انتبه جيدًا لهذه&nbsp; الحالات أثناء استخدام روكلاندا</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلاني قبل استعمالك روكلاندا إن كنت تعتقد أن أيًا مما يلي ينطبق عليك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من جفاف العينين،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا بالربو الشديد أو غير المسيطر عليه جيدًا،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن أصبت سابقًا أو كنت مصابًا حاليًا بعدوى فيروسية في العين سببها فيروس الهربس البسيط.</p><p>&nbsp;</p><p dir="RTL">لا تستعمل روكلاندا أكثر من مرة في اليوم ؛ حيث يمكن أن تتعرض لآثار جانبية أكثر.</p><p>&nbsp;</p><p>الأطفال والمراهقون</p><p dir="RTL">يجب ألا يستخدم الأطفال والمراهقون تحت 18 عامًا روكلاندا؛ لأن أمانه وفعاليته لا يزالان غير معروفين في هذه الفئة العمرية.</p><p>&nbsp;</p><p dir="RTL"><strong>استخدام أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">قد يتفاعل روكلاندا مع أدوية أخرى. أخبر طبيبك أو الصيدلاني إن كنت تستعمل أو استعملت حديثًا أو يحتمل استعمالك لأي أدوية أخرى، خصوصًا أي دواء يحوي نظائر البروستاجلاندين الأخرى كما في لاتانوبروست.</p><p>&nbsp;</p><p>الحمل والرضاعة الطبيعية</p><p dir="RTL">إن كنتِ حاملًا أو ترضعين طبيعيًا أو تعتقدين أنك قد تكونين حاملًا أو تخططين للحمل، فاطلبي النصيحة من طبيبك أو الصيدلاني قبل أخذ هذا الدواء. لا تستعملي روكلاندا إن كنت حاملًا.</p><p>&nbsp;</p><p>قيادة السيارة وتشغيل الآلات</p><p dir="RTL">قد تلاحظ أن رؤيتك مشوشة أو غير طبيعية بعد استعمالك روكلاندا مباشرة. لا تقد السيارة أو تشغل الآلات إلى أن توضح رؤيتك.</p><p>&nbsp;</p><p>يحتوي روكلاندا على كلوريد البنزالكونيوم</p><p dir="RTL">يحتوي هذا الدواء على كلوريد البنزالكونيوم الذي قد تمتصه العدسات اللاصقة المرنة ويتسبب في تغير لونها. يجب أن تزيل العدسات اللاصقة قبل استعمال هذا الدواء ولا تُعِد ارتداءها قبل مرور 15 دقيقة.</p><p>&nbsp;</p><p dir="RTL">قد يسبب كلوريد البنزالكونيوم تهيج العين أيضًا، خصوصًا إن كنت تعاني من جفاف العين أو مشكلات في القرنية (الطبقة الشفافة في مقدمة العين). إن شعرت بإحساس غريب في العين أو الوخز أو الألم بعد استعمال الدواء، فأخبر طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائمًا استعمل هذا الدواء كما أخبرك طبيبك أو الصيدلاني تمامًا. راجع طبيبك أو الصيدلاني إن لم تكن متأكدًا.</p><p>&nbsp;</p><p dir="RTL">استعمل روكلاندا لعينيك فقط (يستخدم على العين).</p><p>&nbsp;</p><p dir="RTL">تقدر الجرعة الموصى بها بقطرة واحدة في العين المصابة مرة واحدة في اليوم مساءً. استعمل الدواء في نفس الوقت تقريبًا كل يوم. لا تستعمله أكثر من مرة يوميًا.</p><p>&nbsp;</p><p>كيفية الاستعمال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغسل يديك قبل البدء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تلمس فوهة القطارة بأصابعك أثناء فتح الزجاجة أو غلقها. يمكن أن يلوث هذا قطرة العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لف غطاء الزجاجة، وضع الغطاء على جانبه فوق سطح نظيف. استمر بإمساك الزجاجة، وتأكد ألا تلامس الفوهة أي شيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسك الزجاجة موجهة للأسفل بين إبهامك وبقية أصابعك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احنِ رأسك للخلف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شد جفنك السفلي بإصبع نظيف لتكوِّن &rsquo;جيبًا&lsquo; بين جفنك وعينك. ستضع القطرة هنا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرب فوهة القطارة للعين. افعل هذا أمام مرآة إن أفادتك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تلمس عينك أو جفنك أو المناطق المحيطة أو الأسطح الأخرى بفوهة القطارة. يمكن أن يلوث هذا قطرة العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضغط برفق على الزجاجة لإدخال قطرة واحدة من روكلاندا في عينك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع فقط قطرة واحدة في عينك كل مرة. إن أخطأت في وضع القطرة، فجرب مجددًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضغط بإصبعك على زاوية العين ناحية الأنف. اضغط مدة دقيقة واحدة بينما تُبقي عينك مغلقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إن كنت تحتاج إلى استعمال قطرة العين في كلتا عينيك</strong>، فأعد هذه الخطوات في عينك الأخرى بينما تُبقِي الزجاجة مفتوحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع غطاء الزجاجة من جديد لإغلاقها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعد الزجاجة إلى العلبة لتحمي القطرات من الضوء إلى حين حاجتك إلى استعمالها مرة أخرى.</p><p>&nbsp;</p><p dir="RTL"><strong>إن كنت تستعمل قطرات أخرى</strong>، فانتظر مدة خمس دقائق على الأقل بعد استعمالها ثم استخدم روكلاندا. إن كنت تستعمل مرهمًا للعين، فيجب أن تجعله آخر ما تضع.</p><p>&nbsp;</p><p>إن استعملت روكلاندا بجرعة أكبر مما يجب</p><p dir="RTL">اشطف عينك بماء دافئ. لا تضع أي قطرات إضافية حتى يحين وقت الجرعة المقررة التالية.</p><p>&nbsp;</p><p>إن نسيت استعمال روكلاندا</p><p dir="RTL">أكمل بالجرعة التالية كما هو مقرر. لا تستعمل جرعة مضاعفة للتعويض عن نسيان جرعة. لا تستعمل أكثر من قطرة واحدة في العين المصابة مرة يوميًا.</p><p>&nbsp;</p><p>إن توقفت عن استعمال روكلاندا</p><p dir="RTL">لا تتوقف عن استعمال روكلاندا دون التحدث مع طبيبك أولًا. إن توقفت عن استعمال روكلاندا فسيكون ضغط عينك خارج السيطرة وهذا قد يؤدي لفقدان البصر.</p><p>&nbsp;</p><p>إن كان لديك أي أسئلة إضافية عن استعمال هذا الدواء، فاسأل طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، بالرغم من أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL">لوحظ الإصابة بالآثار الجانبية التالية عند استعمال روكلاندا وأدوية أخرى تحتوي على لاتانوبروست ونيتاسوديل بمفردهما:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شائعة جدًا (قد تؤثر على أكثر من 1 في كل 10 أشخاص)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الآثار على العين:</em></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار العين، ووجود رواسب صغيرة أمام العين، والألم في مكان وضع القطرات، وزيادة تدريجية في مقدار الصبغة البنية في جزء العين الملون (القزحية) مما يؤدي لتغير لون العين، وزيادة تدريجية في لون (سواد) رموش عينك وطولها وسمكها وعددها.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شائعة (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص)</p><p>&middot;<br />&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الآثار على العين:</em></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى أو التهاب العين، جفاف العين أو تكون تشققات صغيرة في غلاف السائل على سطح العين، خروج إفرازات من العين، شعور بالحكة في جفني العين، تكون غشاوة على العين وضعف طفيف في الرؤية، ألم العين، الإحساس بوجود رمل أو شيء ما في العين، احمرار عام في العين بعد فترة قصيرة من وضع القطرات، نقاط أو بقع من الاحمرار بالعين، التهاب الملتحمة (التهاب العين أو الأوعية الدموية البارزة) الناجم عن تفاعل تحسسي، وسيلان العين، وتورم حول العين، وتقشر الجفن، وتشوش الرؤية،</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الآثار الجانبية العامة</em></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار جلد الوجه أو الشعور بحكة فيه</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غير شائعة (قد تؤثر على ما يصل إلى 1 من كل 100 شخص)</p><p>&middot;<br />&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الآثار على العين:</em></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة ضغط السائل داخل العين، والتهاب جزء العين الملون (القزحية)، وانتفاخ القزحية، وزيادة تجعد الطبقة الشفافة فوق العين عند التقائها مع الجفن السفلي، والعمى، وتشوش الرؤية أو ازدواجها أو رؤية هالة حول الضوء، وانسداد القناة الدمعية، وانتشار نقاط ملونة صغيرة فوق سطح العين، وجفاف جفن العين، وجفاف العين الناجم عن التهاب غدد جفن العين، وحساسية العين، والعيون اللامعة/زجاجية المظهر، والتعب، وخدر أو حرقة العين، وانقلاب غير طبيعي للجفن السفلي إلى الخارج، فقدان رموش العين، وأمراض العين المرتبطة بداء السكري، وزيادة الحساسية للضوء، وتغير لون جلد جفن العين</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الآثار الجانبية على باقي أجزاء الجسم</em></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأنف، ونزيف الأنف، وشعور مزعج والإحساس بالألم في الأنف، والصداع، والدوخة، والمرض(القيء)، واحمرار الجلد والشعور بالحكة فيه، وجفاف الجلد، وتغلظ الجلد، وألم عضلي أو تشنج، أو الضعف ، وألم في المفصل، وألم في الفك، وخدش الجلد، والتهاب الغضروف، وألم في الصدر (الذبحة الصدرية)، والإحساس الزائد بضربات القلب (الخفقان)، والربو، وضيق التنفس (صعوبة التنفس)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادرة (قد تؤثر على ما يصل إلى 1 من كل 1000 شخص)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الآثار على العين:</em></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ سطح العين أو خدشه مع تضرره، وانتفاخ المنطقة المحيطة بالعين (تورم ما حول المحجر)، ونمو رموش العين في اتجاه خاطئ أو نمو صف زائد منها، وظهور ندوب على سطح العين، وامتلاء جزء العين الملون بالسائل (كيس القزحية)، وتفاعل جلدي تحسسي على جفون العين، وسواد جلد جفون العين، وإصابة العين بعدوى فيروسية يسببها فيروس الهربس البسيط (HSV).</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الآثار الجانبية على باقي أجزاء الجسم</em></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم الربو، والشعور بحكة شديدة في الجلد</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادرة جدًا (قد تؤثر على ما يصل إلى 1 من كل 10,000 شخص)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الآثار على العين:</em></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مظهر العين الغائرة (تعمق ثلم العين).</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الآثار الجانبية على باقي أجزاء الجسم</em></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم الذبحة الصدرية لدى المرضى المصابين أيضًا بأمراض القلب</p><p>&nbsp;</p><p>الإبلاغ عن الآثار الجانبية</p><p dir="RTL">إن زادت حدة أي من الآثار الجانبية، أو إن لاحظت تعرضك لأي آثار غير مدرجة في</p><p dir="RTL"><br />هذه النشرة، فيرجى إبلاغ طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; طريقة تخزين روكلاندا</p><p><strong>&nbsp;</strong></p><p dir="RTL">يحفظ بعيدًا عن أنظار ومتناول أيدي الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء بعد انتهاء تاريخ صلاحيته المدون على الزجاجة والعلبة بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر.</p><p>&nbsp;</p><p dir="RTL">الزجاجات غير المفتوحة: خزنها في الثلاجة (2 &ndash; 8) درجة مئوية &nbsp;بمجرد فتحه، لا تخزنه في درجة حرارة أعلى من &nbsp;25 درجة مئوية.</p><p>&nbsp;</p><p dir="RTL">خزنها في العلبة الأصلية لحمايتها من الضوء.</p><p>&nbsp;</p><p dir="RTL">تخلص من الزجاجة بعد 4 أسابيع من فتحها للوقاية من التلوث واستعمل أخرى جديدة.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp; المواد الفعالة هي لاتانوبروست ونيتارسوديل. يحتوي كل مل واحد من المحلول على 50 ميكروجرام من لاتانوبروست و 200 ميكروجرام من نيتارسوديل (في صورة ميسيلات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; المواد المضافة الأخرى هي كلوريد البنزالكونيوم (راجع الجزء 2 تحت عنوان &rsquo;يحتوي روكلاندا على كلوريد البنزالكونيوم&lsquo;)، ومانيتول، وحمض البوريك، وهيدروكسيد الصوديوم (لتعديل درجة الحموضة)، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">قطرات للعين ومحلول.</p><p dir="RTL" style="text-align:right; text-indent:50px">روكلاندا هو محلول قطرات للعين سائل شفاف داخل زجاجة بلاستيكية. تحتوي كل زجاجة على 2.5 مل من الدواء، وتحتوي كل عبوة على زجاجة واحدة بغطاء لولبي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;حامل تفويض التسوق</p><p dir="RTL">سانتن او واي</p><p dir="RTL">نيتيهانكاتو 20، 33720 تامبير، فنلندا</p><p>&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p>أيري للمستحضرات الدوائية أيرلندا، المحدودة</p><p>&nbsp;حديقة أثلون للأعمال والتكنولوجيا، طريق دبلن،</p><p>&nbsp;جاريكاسل، أثلون، كو ويستميث،</p><p>، أيرلنداN37 DW40</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة المسؤولة عن الموافقة على التشغيلات</strong></p><p dir="RTL">&nbsp;سانتن او واي</p><p>كيلوبورتينكاتو 1، 33100 تامبير، فنلندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	تمت مراجعة هذه النشرة آخر مرة في  05/2022.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Roclanda 50 micrograms/ml + 200 micrograms/ml eye drops, solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml of solution contains 50 micrograms latanoprost and 200 micrograms netarsudil (as mesylate). Excipient(s) with known effect
Each ml of solution contains 200 micrograms benzalkonium chloride. 
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops, solution.

Clear, colourless solution, pH 5 (approximately). Osmolality: 280 mOsm/Kg.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Roclanda is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Roclanda should only be initiated by an ophthalmologist or a healthcare professional qualified in ophthalmology.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em>Use in adults, including the elderly</em></p><p>The recommended dosage is one drop in the affected eye(s) once daily in the evening. Patients should not instill more than one drop in the affected eye(s) each day.</p><p>&nbsp;</p><p>If one dose is missed, treatment should continue with the next dose in the evening.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Roclanda in children below the age of 18 years have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Ocular use.</p><p>&nbsp;</p><p>Data on potential interactions specific to latanoprost + netarsudil are described in section 4.5. If latanoprost + netarsudil is to be used concomitantly with other topical ophthalmic medicinal products, each medicinal product should be administered at least five minutes apart. Due to netarsudil&rsquo;s vasodilating properties, other eye drops should be administered before latanoprost + netarsudil. Eye ointments should be administered last.</p><p>&nbsp;</p><p>Contact lenses should be removed prior to instillation of latanoprost + netarsudil and may be reinserted 15 minutes following its administration (see section 4.4).</p><p>&nbsp;</p><p>As with any eye drops, to reduce possible systemic absorption, it is recommended that the lachrymal sac be compressed at the medial canthus (punctal occlusion) for one minute. This should be performed immediately following the instillation of each drop.</p><p>&nbsp;</p><p>The tip of the dispensing container should avoid contacting the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Iris pigmentation</u></p><p>&nbsp;</p><p>Latanoprost may gradually change eye colour by increasing the amount of brown pigment in the iris. Before treatment is instituted, patients should be informed of the possibility of a permanent change in eye colour. Unilateral treatment can result in permanent heterochromia.</p><p>&nbsp;</p><p>Increased iris pigmentation has not been shown to have any negative clinical sequelae and treatment with medicinal products containing latanoprost can be continued if iris pigmentation ensues. However, patients should be monitored regularly and if the clinical situation warrants, treatment with medicinal products containing latanoprost may be discontinued.</p><p>&nbsp;</p><p><u>Herpetic keratitis condition</u></p><p>&nbsp;</p><p>Medicinal product(s) containing latanoprost should be used with caution in patients with a history of herpetic keratitis, and should be avoided in cases of active herpes simplex keratitis and in patients with a history of recurrent herpetic keratitis specifically associated with prostaglandin analogues.</p><p>&nbsp;</p><p><u>Macular oedema risk</u></p><p>&nbsp;</p><p>Reports of macular oedema with medicinal products containing latanoprost have occurred mainly in aphakic patients, in pseudophakic patients with torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for cystoid macular oedema (such as diabetic retinopathy and retinal vein occlusion). Medicinal products containing latanoprost should be used with caution in aphakic patients, in pseudophakic patients with torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for cystoid macular oedema.</p><p><u>&nbsp;</u></p><p><u>Iritis/uveitis risk</u></p><p>&nbsp;</p><p>In patients with known predisposing risk factors for iritis/uveitis, medicinal products containing latanoprost can be used with caution.</p><p><u>&nbsp;</u></p><p><u>Asthma exacerbation</u></p><p>&nbsp;</p><p>There is limited experience of latanoprost use in patients with asthma, but some cases of exacerbation of asthma and/or dyspnoea were reported in post marketing experience. Asthmatic patients should therefore be treated with caution until there is sufficient experience with the combination.</p><p>&nbsp;</p><p><u>Periorbital skin discolouration</u></p><p>&nbsp;</p><p>Periorbital skin discolouration has been observed on treatment with medicinal products containing latanoprost, the majority of reports being in Japanese patients. Experience to date shows that periorbital skin discolouration is not permanent and in some cases has reversed while continuing treatment with latanoprost.</p><p>&nbsp;</p><p><u>Eyelash changes</u></p><p>&nbsp;</p><p>Treatment with medicinal products containing latanoprost may gradually change eyelashes and vellus hair in the treated eye and surrounding areas; these changes include increased length, thickness, pigmentation, number of lashes or hairs and misdirected growth of eyelashes. Eyelash changes are reversible upon discontinuation of treatment.</p><p>&nbsp;</p><p><u>Benzalkonium chloride content</u></p><p>&nbsp;</p><p>This medicinal product contains benzalkonium chloride.</p><p>Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface and is known to discolour soft contact lenses. It should be used with caution in dry eye patients and in patients where the cornea may be compromised.</p><p>Patients should be monitored in case of prolonged use.</p><p>&nbsp;</p><p>The efficacy of Roclanda has not been studied beyond 12 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro </em>interaction studies have shown that precipitation can occur when eye drops containing thimerosal are mixed with latanoprost + netarsudil. Administer other eye drops at least five minutes apart (see section 4.2).</p><p>&nbsp;</p><p><em>In vitro </em>studies have indicated netarsudil has the potential to inhibit CYP450 isoenzymes in the cornea, however no clinical evidence of local pharmacokinetic interactions has been observed to date.</p><p>&nbsp;</p><p>There have been reports of paradoxical elevations in IOP following the concomitant ophthalmic administration of two prostaglandin analogues. Therefore, the use of two or more prostaglandins, prostaglandin analogues or prostaglandin derivatives is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data from the use of latanoprost + netarsudil in pregnant women.</p><p>&nbsp;</p><p>No effects during pregnancy are anticipated, since systemic exposure to netarsudil is negligible (see section 5.2). Animal studies with intravenous administration of netarsudil do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant exposures (see section 5.3).</p><p>&nbsp;</p><p>Latanoprost has potentially harmful pharmacological effects during pregnancy and/or on the fetus/newborn child (see section 5.3).</p><p>&nbsp;</p><p>Therefore, latanoprost + netarsudil should not be used during pregnancy.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>It is unknown whether netarsudil/metabolites are excreted in human milk. However, while no effects on the breastfed newborn/infant are anticipated since the systemic exposure of breast-feeding women to netarsudil is expected to be negligible, no relevant clinical data are available (see section 5.2).</p><p>Latanoprost and its metabolites may pass into human milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Roclanda therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no data on the effects of netarsudil on male or female fertility. However, no effects are anticipated, since systemic exposure to netarsudil is negligible (see section 5.2). Latanoprost has not been found to have any effect on male or female fertility in animal studies (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Roclanda has negligible influence on the ability to drive and use machines.</p><p>If transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most common ocular adverse reaction observed is conjunctival hyperaemia which was reported in 46% of patients. Other ocular adverse reactions reported are instillation site pain (14%), cornea verticillata (12%) and eye pruritis (7%). The majority of adverse reactions reported in clinical studies using Roclanda were ocular, mild to moderate in severity. Based on clinical studies, conjunctival hyperaemia which was reported in approximately 46% of patients led to discontinuation in 4.9% of patients.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The following adverse reactions have been reported with latanoprost + netarsudil, dosed once daily, and during clinical studies and post-marketing surveillance with the individual components latanoprost and netarsudil. Adverse reactions are presented according to the MedDRA system organ classification. Within each system organ class, the adverse reactions are classified by frequency according to the following convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to</p><p>&lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:618px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Classification</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>herpetic keratitis2</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>hypersensitivity,</p><p>vomiting</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>headache,</p><p>muscle contractions involuntary, dizziness,</p><p>visual field defect3</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>conjunctival hyperaemia1, cornea verticillata1, instillation site pain,</p><p>iris hyperpigmentation2,</p><p>eyelash and vellus hair changes of the eyelid (increased length, thickness,</p><p>pigmentation and number of eyelashes)2</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>conjunctival haemorrhage, vision blurred,</p></td></tr><tr><td rowspan="62" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="19" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>lacrimation increased,</p></td></tr><tr><td style="vertical-align:top"><p>erythema of eyelid,</p></td></tr><tr><td style="vertical-align:top"><p>eye pruritus,</p></td></tr><tr><td style="vertical-align:top"><p>eye irritation,</p></td></tr><tr><td style="vertical-align:top"><p>visual acuity reduced,</p></td></tr><tr><td style="vertical-align:top"><p>eyelid oedema,</p></td></tr><tr><td style="vertical-align:top"><p>punctate keratitis,</p></td></tr><tr><td style="vertical-align:top"><p>corneal disorder,</p></td></tr><tr><td style="vertical-align:top"><p>conjunctival oedema,</p></td></tr><tr><td style="vertical-align:top"><p>conjunctivitis allergic,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>eye pain,</p></td></tr><tr><td style="vertical-align:top"><p>dry eye,</p></td></tr><tr><td style="vertical-align:top"><p>foreign body sensation in eyes,</p></td></tr><tr><td style="vertical-align:top"><p>eyelid margin crusting,</p></td></tr><tr><td style="vertical-align:top"><p>blepharitis,</p></td></tr><tr><td style="vertical-align:top"><p>instillation site erythema,</p></td></tr><tr><td style="vertical-align:top"><p>instillation site discomfort,</p></td></tr><tr><td style="vertical-align:top"><p>vital dye staining cornea present</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>eyelids pruritus,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>conjunctival disorder,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>corneal opacity,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eye discharge,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>corneal deposits,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>conjunctivitis,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dacryostenosis acquired,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eye inflammation,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eye paraesthesia,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>conjunctival follicles,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eye swelling,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>meibomian gland dysfunction,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>corneal pigmentation,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>diplopia,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>noninfective conjunctivitis,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abnormal sensation in eye,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>keratitis,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>refraction disorder,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anterior chamber flare,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>conjunctival irritation,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>intraocular pressure increased,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eyelid rash,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eyelid skin dryness,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>growth of eyelashes,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>lacrimal disorder,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>iritis,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>visual impairment,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>corneal dystrophy,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>instillation site dryness,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>instillation site pruritus,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>instillation site reaction,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eye complication associated with</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>device, fatigue,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>instillation site paraesthesia,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>macular oedema including cystoid</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>macular oedema2,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>uveitis2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ocular hyperaemia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>diabetic retinopathy3,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eye allergy3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ocular discomfort,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eyelid disorder3,</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:618px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Classification</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ectropion3, lenticular opacities3, asthenopia3,</p><p>episcleral hyperaemia3, halo vision3,</p><p>anterior chamber inflammation3, blindness3, conjunctivochalasis,</p><p>eczema eyelids3, glaucoma3,</p><p>iris adhesions3, iris bombe3,</p><p>ocular hypertension3, instillation site irritation3, glassy eyes3,</p><p>instillation site oedema3, conjunctival staining3,optic nerve cup/disc ratio increased3, madarosis3, blepharal pigmentation,</p><p>eye disorder, retinal haemorrhage, photophobia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>corneal oedema2, corneal erosion2, periorbital oedema2, trichiasis2, distichiasis2,</p><p>iris cyst2,</p><p>localised skin reaction on the eyelids2, darkening of the palpebral skin of the eyelids2,</p><p>pseudopemphigoid of ocular conjunctiva2</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>periorbital and lid changes resulting in</p><p>deepening of the eyelid sulcus2</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>angina2,</p><p>palpitations2</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>angina unstable2</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>epistaxis,</p><p>nasal congestion, nasal discomfort3, rhinalgia3</p><p>asthma2, dyspnoea2</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>asthma exacerbation2</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>dermatitis contact</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>lichenification, dry skin, erythema,</p><p>skin disorder,</p><p>dermatitis allergic3 petechiae, eczema</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>pruritus2</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>pain in jaw, myalgia2,</p><p>arthralgia2, polychondritis3,</p><p>muscular weakness,</p><p>Sjogren&rsquo;s syndrome</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site</p><p>conditions</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>chest pain2</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>excoriation3</p></td></tr></tbody></table><p>1 See <em>Description of selected adverse reactions </em>for further information 2 Additional adverse reaction observed with latanoprost monotherapy 3 Additional adverse reaction observed with netarsudil monotherapy</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Conjunctival hyperaemia</em></p><p>Conjunctival hyperaemia was the most frequently reported adverse reaction associated with latanoprost</p><p>+ netarsudil treatment in clinical studies and it is attributed to the vasodilation effect of the Rho kinase inhibitor medicinal product class. Conjunctival hyperaemia was typically mild in severity and sporadic. However, there was a relatively small proportion of subjects with moderate or severe hyperaemia who discontinued treatment because of this adverse reaction (5.0% in Phase 3 clinical studies).</p><p>&nbsp;</p><p><em>Cornea verticillata</em></p><p>Cornea verticillata occurred in approximately 13% of the patients in controlled Phase 3 clinical studies. The cornea verticillata seen in latanoprost + netarsudil-treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes in patients. The majority of cornea verticillata resolved upon discontinuation of treatment. The incidence of cornea verticillata was higher in certain subpopulations: elderly (&ge;65 years) versus non-elderly (18.8 vs. 11.5%); males versus females (18.8 vs. 13.0%) and in white versus other races (21.7 vs. 2.5%).</p><p>&nbsp;</p><p><em>Iris pigmentation</em></p><p>Roclanda contains latanoprost which is a prostaglandin F2&alpha; analogue. The majority of adverse reactions associated with latanoprost are ocular in nature. In a 5-year latanoprost safety study, 33% of patients developed iris pigmentation (section 4.4).</p><p>&nbsp;</p><p>This change in eye colour has predominantly been seen in patients with mixed coloured irides, i.e. blue-brown, grey-brown, yellow-brown and green-brown. In studies with latanoprost, the onset of the change is usually within the first 8 months of treatment, rarely during the second or third year, and has not been seen after the fourth year of treatment. The rate of progression of iris pigmentation decreases with time and is stable for five years. The effect of increased pigmentation beyond five years has not been evaluated. The iris colour change is slight in the majority of cases and often not observed clinically. The incidence in patients with mixed colour irides ranged from 7 to 85%, with yellow- brown irides having the highest incidence. In patients with homogeneously blue eyes, no change has been observed and in patients with homogeneously grey, green or brown eyes, the change has only rarely been seen.</p><p>&nbsp;</p><p>The colour change is due to increased melanin content in the stromal melanocytes of the iris and not to an increase in number of melanocytes. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery in affected eyes, but the entire iris or parts of it may become more brownish. No further increase in brown iris pigment has been observed after discontinuation of treatment. It has not been associated with any symptom or pathological changes in clinical studies to date.</p><p>&nbsp;</p><p>Neither naevi nor freckles of the iris have been affected by treatment. Accumulation of pigment in the trabecular meshwork or elsewhere in the anterior chamber has not been observed in clinical studies.</p><p>&nbsp;</p><p><u>Other special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>With the exception of cornea verticillata (see above), no difference in the safety profile for latanoprost</p><p>+ netarsudil has been observed between subjects aged &lt;65 or &ge;65 years.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p>&nbsp;</p><p>For <strong>United Arab Emirates</strong>, you can report any side effects through the Ministry of health and prevention:</p><p>Pharmacovigilance and Medical Device Section</p><p>P.O.Box : 1853</p><p>Tel: 800011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department</p><p>Ministry of Health and Prevention</p><p>Dubai, U.A.E</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Systemic exposure to the netarsudil component of latanoprost + netarsudil following topical ocular administration has been shown to be negligible.</p><p>&nbsp;</p><p>Apart from ocular irritation and conjunctival hyperaemia, no other ocular side effects are known if latanoprost is overdosed.</p><p>&nbsp;</p><p>If latanoprost is accidentally ingested the following information may be useful: one bottle contains 125 micrograms latanoprost. More than 90% is metabolised during the first pass through the liver. Intravenous infusion of 3 micrograms/kg in healthy volunteers induced no symptoms, but a dose of 5.5-10 micrograms/kg caused nausea, abdominal pain, dizziness, fatigue, hot flushes and sweating. In monkeys, latanoprost has been infused intravenously in doses of up to 500 micrograms/kg without major effects on the cardiovascular system.</p><p>&nbsp;</p><p>Intravenous administration of latanoprost in monkeys has been associated with transient bronchoconstriction. However, in patients with moderate bronchial asthma, bronchoconstriction was not induced by latanoprost when applied topically on the eyes in a dose of seven times the clinical dose of latanoprost.</p><p>&nbsp;</p><p>If topical overdose of latanoprost + netarsudil should occur, the eye(s) may be flushed with tap water. Treatment of an overdose would include supportive and symptomatic therapy.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Ophthalmologicals, antiglaucoma preparations and miotics, ATC code: S01EE51</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Roclanda contains two active substances: latanoprost and netarsudil. These two components lower IOP by increasing the outflow of aqueous humor. Although both latanoprost and netarsudil lower IOP by increasing aqueous humor outflow, their mechanisms of action are different.</p><p>&nbsp;</p><p>Studies in animal and man suggest that the main mechanism of action for netarsudil, a Rho kinase inhibitor, is increased trabecular outflow. These studies also suggest that netarsudil lowers IOP by reducing episcleral venous pressure.</p><p>&nbsp;</p><p>Studies in animal and man indicate that the main mechanism of action for latanoprost, a prostaglandin F2&alpha; analoque, is increased uveoscleral outflow, although some increase in outflow facility (decrease in outflow resistance) has been reported in man.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>Roclanda was evaluated in 3 randomized, double-blind, multicentre Phase 3 clinical studies in 1,686 patients with open-angle glaucoma and ocular hypertension. Studies 301 and 302 enrolled subjects with IOP &lt;36 mmHg and compared IOP lowering effect of latanoprost + netarsudil dosed once daily to individually administered netarsudil 0.02% once daily and latanoprost 0.005% once</p><p>daily. The treatment duration was 12 months for Study 301 and 3 months for Study 302. The median age of study participants was 66 years (range 18 to 99 years). Study 303 assessed the ocular hypotensive efficacy of latanoprost + netarsudil relative to Ganfort<sup>&reg;</sup> (bimatoprost 0.03%/timolol 0.5%). The treatment duration was 6 months.</p><p>&nbsp;</p><p>Studies 301 and 302 were designed to show superiority of latanoprost + netarsudil when dosed once daily in the evening over its individual components netarsudil 0.02% once daily and latanoprost 0.005% once daily. The primary efficacy outcome measure was least squares (LS) mean IOP at each of 9 timepoints measured at 08:00, 10:00 and 16:00 on day 15, day 43 and day 90. The average IOP lowering effect of latanoprost + netarsudil was 1 to 3 mmHg greater than monotherapy with either netarsudil 0.02% or latanoprost 0.005% throughout 3 months (Figures 1 and 2). In Study 301 IOP reductions were maintained, showing statistical superiority of latanoprost + netarsudil throughout the 12-month treatment period. In all cases, the differences in the LS mean IOP were clinically relevant and statistically significant (p &lt; 0.0001) through month 3. Approximately 30% of subjects included in the Phase 3 studies had a baseline IOP of &ge;27 mmHg (132, 136 and 143 in the latanoprost + netarsudil, latanoprost and netarsudil treatment groups, respectively). In these subjects, latanoprost + netarsudil showed statistically significantly superior IOP-lowering efficacy to each of its components at all time points. Across both studies, compared to latanoprost alone, the combination product reduced IOP by a further 1.7 mmHg to 3.7 mmHg, and compared to netarsudil alone by a further 3.4 mmHg to 5.9 mmHg.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="Group_x0020_81"
 o:spid="_x0000_s1073" style='position:absolute;margin-left:118.55pt;
 margin-top:40.25pt;width:410.5pt;height:193.05pt;z-index:-54568;
 mso-position-horizontal-relative:page' coordorigin="2371,805" coordsize="8210,3861"
 o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:line id="Line_x0020_113" o:spid="_x0000_s1074" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="2379,4609" to="2379,4609"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokecolor="#878787"/>
 <v:shape id="AutoShape_x0020_112" o:spid="_x0000_s1075" style='position:absolute;
  top:12394;width:8195;height:58;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="8195,58" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m2379,-7785r8194,m2379,-7785r,57m3289,-7785r,57m4200,-7785r,57m5111,-7785r,57m6020,-7785r,57m6931,-7785r,57m7842,-7785r,57m8752,-7785r,57m9662,-7785r,57m10573,-7785r,57e"
  filled="f" strokecolor="#878787">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2379,4609;10573,4609;2379,4609;2379,4666;3289,4609;3289,4666;4200,4609;4200,4666;5111,4609;5111,4666;6020,4609;6020,4666;6931,4609;6931,4666;7842,4609;7842,4666;8752,4609;8752,4666;9662,4609;9662,4666;10573,4609;10573,4666"
   o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="AutoShape_x0020_111" o:spid="_x0000_s1076" style='position:absolute;
  top:12182;width:7284;height:550;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="7284,550" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m2834,-8250r910,295l4655,-7912t911,-507l6476,-8081r910,-43m8297,-8461r911,380l10118,-8166e"
  filled="f" strokecolor="#4f81bd" strokeweight="2pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2834,3933;3744,4228;4655,4271;5566,3764;6476,4102;7386,4059;8297,3722;9208,4102;10118,4017"
   o:connectangles="0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Picture_x0020_110" o:spid="_x0000_s1077" type="#_x0000_t75"
  style='position:absolute;left:2766;top:3865;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_109" o:spid="_x0000_s1078" type="#_x0000_t75"
  style='position:absolute;left:3676;top:4161;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_108" o:spid="_x0000_s1079" type="#_x0000_t75"
  style='position:absolute;left:4587;top:4203;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_107" o:spid="_x0000_s1080" type="#_x0000_t75"
  style='position:absolute;left:5497;top:3696;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_106" o:spid="_x0000_s1081" type="#_x0000_t75"
  style='position:absolute;left:6408;top:4034;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_105" o:spid="_x0000_s1082" type="#_x0000_t75"
  style='position:absolute;left:7318;top:3992;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_104" o:spid="_x0000_s1083" type="#_x0000_t75"
  style='position:absolute;left:8229;top:3654;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_103" o:spid="_x0000_s1084" type="#_x0000_t75"
  style='position:absolute;left:9139;top:4034;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_102" o:spid="_x0000_s1085" type="#_x0000_t75"
  style='position:absolute;left:10050;top:3950;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:shape id="AutoShape_x0020_101" o:spid="_x0000_s1086" style='position:absolute;
  top:12098;width:7284;height:888;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="7284,888" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m2834,-9434r910,296l4655,-8842t911,-803l6476,-9223r910,211m8297,-9730r911,381l10118,-8927e"
  filled="f" strokecolor="#c0504d" strokeweight="2pt">
  <v:stroke dashstyle="dot"/>
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2834,2665;3744,2961;4655,3257;5566,2454;6476,2876;7386,3087;8297,2369;9208,2750;10118,3172"
   o:connectangles="0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="Picture_x0020_100" o:spid="_x0000_s1087" type="#_x0000_t75"
  style='position:absolute;left:2764;top:2596;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image002.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_99" o:spid="_x0000_s1088" type="#_x0000_t75"
  style='position:absolute;left:3675;top:2891;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image002.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_98" o:spid="_x0000_s1089" type="#_x0000_t75"
  style='position:absolute;left:4586;top:3188;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image003.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_97" o:spid="_x0000_s1090" type="#_x0000_t75"
  style='position:absolute;left:5495;top:2385;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image004.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_96" o:spid="_x0000_s1091" type="#_x0000_t75"
  style='position:absolute;left:6406;top:2807;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image003.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_95" o:spid="_x0000_s1092" type="#_x0000_t75"
  style='position:absolute;left:7317;top:3018;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image002.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_94" o:spid="_x0000_s1093" type="#_x0000_t75"
  style='position:absolute;left:8228;top:2300;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image005.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_93" o:spid="_x0000_s1094" type="#_x0000_t75"
  style='position:absolute;left:9137;top:2680;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image003.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_92" o:spid="_x0000_s1095" type="#_x0000_t75"
  style='position:absolute;left:10048;top:3102;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image004.png"
   o:title=""/>
 </v:shape><v:shape id="AutoShape_x0020_91" o:spid="_x0000_s1096" style='position:absolute;
  top:12394;width:7284;height:465;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="7284,465" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m2834,-9391r910,169l4655,-9138t911,-211l6476,-9094r910,42m8297,-9307r911,297l10118,-8926e"
  filled="f" strokecolor="#f79646" strokeweight="2pt">
  <v:stroke dashstyle="dash"/>
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2834,3003;3744,3172;4655,3256;5566,3045;6476,3300;7386,3342;8297,3087;9208,3384;10118,3468"
   o:connectangles="0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="Picture_x0020_90" o:spid="_x0000_s1097" type="#_x0000_t75"
  style='position:absolute;left:2769;top:2938;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image006.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_89" o:spid="_x0000_s1098" type="#_x0000_t75"
  style='position:absolute;left:3678;top:3107;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image007.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_88" o:spid="_x0000_s1099" type="#_x0000_t75"
  style='position:absolute;left:4589;top:3191;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image007.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_87" o:spid="_x0000_s1100" type="#_x0000_t75"
  style='position:absolute;left:5500;top:2980;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image008.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_86" o:spid="_x0000_s1101" type="#_x0000_t75"
  style='position:absolute;left:6411;top:3234;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image007.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_85" o:spid="_x0000_s1102" type="#_x0000_t75"
  style='position:absolute;left:7320;top:3276;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image009.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_84" o:spid="_x0000_s1103" type="#_x0000_t75"
  style='position:absolute;left:8231;top:3022;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image009.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_83" o:spid="_x0000_s1104" type="#_x0000_t75"
  style='position:absolute;left:9142;top:3318;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image007.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_82" o:spid="_x0000_s1105" type="#_x0000_t75"
  style='position:absolute;left:10052;top:3402;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image008.png"
   o:title=""/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="548" height="159" src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image010.gif" /><!--[if gte vml 1]><v:group
 id="Group_x0020_78" o:spid="_x0000_s1070" style='position:absolute;
 margin-left:167.4pt;margin-top:21.7pt;width:25.2pt;height:5.7pt;z-index:-54544;
 mso-position-horizontal-relative:page' coordorigin="3348,434" coordsize="504,114"
 o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:line id="Line_x0020_80" o:spid="_x0000_s1071" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="3348,491" to="3852,491"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokecolor="#4f81bd" strokeweight="2pt"/>
 <v:shape id="Picture_x0020_79" o:spid="_x0000_s1072" type="#_x0000_t75"
  style='position:absolute;left:3542;top:434;width:114;height:114;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image011.png"
   o:title=""/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="37" height="7" src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image012.gif" /><!--[if gte vml 1]><v:group
 id="Group_x0020_75" o:spid="_x0000_s1067" style='position:absolute;
 margin-left:279.15pt;margin-top:21.1pt;width:25.2pt;height:6.95pt;z-index:-54520;
 mso-position-horizontal-relative:page' coordorigin="5583,422" coordsize="504,139"
 o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:line id="Line_x0020_77" o:spid="_x0000_s1068" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="5583,491" to="6087,491"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokecolor="#c0504d" strokeweight="2pt">
  <v:stroke dashstyle="dot"/>
 </v:line><v:shape id="Picture_x0020_76" o:spid="_x0000_s1069" type="#_x0000_t75"
  style='position:absolute;left:5765;top:421;width:139;height:139;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image002.png"
   o:title=""/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="37" height="9" src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image013.gif" /><!--[if gte vml 1]><v:group
 id="Group_x0020_72" o:spid="_x0000_s1064" style='position:absolute;
 margin-left:395.15pt;margin-top:21.75pt;width:25.2pt;height:5.5pt;z-index:-54496;
 mso-position-horizontal-relative:page' coordorigin="7903,435" coordsize="504,110"
 o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:line id="Line_x0020_74" o:spid="_x0000_s1065" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="7903,491" to="8407,491"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokecolor="#f79646" strokeweight="2pt">
  <v:stroke dashstyle="dash"/>
 </v:line><v:shape id="Picture_x0020_73" o:spid="_x0000_s1066" type="#_x0000_t75"
  style='position:absolute;left:8098;top:434;width:110;height:110;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image014.png"
   o:title=""/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="37" height="7" src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image015.gif" /><strong>Figure 1: Study 301 mean IOP (mmHg) by treatment group and treatment difference in mean IOP</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:648px"><tbody><tr><td colspan="10" style="vertical-align:top"><p>Roclanda&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Netarsudil&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Latanoprost</p><p>23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Baseline&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Baseline&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Baseline</p><p>8AM&nbsp;&nbsp;&nbsp; 10AM&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8AM&nbsp;&nbsp;&nbsp; 10AM&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8AM&nbsp;&nbsp;&nbsp; 10AM</p><p>22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4PM&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4PM&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4PM 24.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23.4</p><p>21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22.4</p><p>20</p><p>19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19.3</p><p>18.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18.4</p><p>18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18.1</p><p>17.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.6</p><p>17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.4</p><p>17.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16.7</p><p>16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16.1</p><p>15.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15.4</p><p>15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15.2</p><p>14</p><p>Day 15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 90 (8AM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (10AM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (4PM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (8AM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (10AM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (4PM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (8AM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (10AM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (4PM)</p></td></tr><tr><td style="vertical-align:top"><p><strong>latanoprost + netarsudil vs. netarsudil</strong></p><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p><strong>3.0</strong></p><p><strong>&nbsp;</strong></p><p><strong>(2.5, 3.6)</strong></p></td><td style="vertical-align:top"><p><strong>3.0</strong></p><p><strong>&nbsp;</strong></p><p><strong>(2.4, 3.6)</strong></p></td><td style="vertical-align:top"><p><strong>2.4</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.9, 3.0)</strong></p></td><td style="vertical-align:top"><p><strong>3.2</strong></p><p><strong>&nbsp;</strong></p><p><strong>(2.6, 3.8)</strong></p></td><td style="vertical-align:top"><p><strong>2.9</strong></p><p><strong>&nbsp;</strong></p><p><strong>(2.3, 3.5)</strong></p></td><td style="vertical-align:top"><p><strong>2.3</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.7, 2.8)</strong></p></td><td style="vertical-align:top"><p><strong>3.1</strong></p><p><strong>&nbsp;</strong></p><p><strong>(2.5, 3.8)</strong></p></td><td style="vertical-align:top"><p><strong>3.2</strong></p><p><strong>&nbsp;</strong></p><p><strong>(2.5, 3.8)</strong></p></td><td style="vertical-align:top"><p><strong>2.0</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.4, 2.6)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>latanoprost + netarsudil vs. latanoprost</strong></p><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p><strong>2.3</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.7, 2.8)</strong></p></td><td style="vertical-align:top"><p><strong>2.6</strong></p><p><strong>&nbsp;</strong></p><p><strong>(2.0, 3.2)</strong></p></td><td style="vertical-align:top"><p><strong>2.3</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.8, 2.9)</strong></p></td><td style="vertical-align:top"><p><strong>1.7</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.1, 2.4)</strong></p></td><td style="vertical-align:top"><p><strong>1.9</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.3, 2.5)</strong></p></td><td style="vertical-align:top"><p><strong>1.7</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.1, 2.2)</strong></p></td><td style="vertical-align:top"><p><strong>1.5</strong></p><p><strong>&nbsp;</strong></p><p><strong>(0.9, 2.1)</strong></p></td><td style="vertical-align:top"><p><strong>1.7</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.1, 2.3)</strong></p></td><td style="vertical-align:top"><p><strong>1.3</strong></p><p><strong>&nbsp;</strong></p><p><strong>(0.7, 1.9)</strong></p></td></tr></tbody></table><p>The LS mean IOP at each post-baseline time point was derived using an analysis of covariance adjusted for baseline IOP and based on observed data for all randomized subjects (238 in latanoprost + netarsudil group, 244 in netarsudil group, 236 in latanoprost group).</p><p><!--[if gte vml 1]><v:group
 id="Group_x0020_34" o:spid="_x0000_s1026" style='position:absolute;
 margin-left:112.45pt;margin-top:34.7pt;width:413.75pt;height:201.6pt;
 z-index:-54472;mso-position-horizontal-relative:page' coordorigin="2249,694"
 coordsize="8275,4032" o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:shape id="AutoShape_x0020_71" o:spid="_x0000_s1027" style='position:absolute;
  top:11882;width:8260;height:3955;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="8260,3955" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m2257,-7214r,-3898m2257,-7214r8259,m2257,-7214r,57m3174,-7214r,57m4092,-7214r,57m5010,-7214r,57m5927,-7214r,57m6845,-7214r,57m7763,-7214r,57m8681,-7214r,57m9598,-7214r,57m10516,-7214r,57e"
  filled="f" strokecolor="#878787">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2257,4668;2257,770;2257,4668;10516,4668;2257,4668;2257,4725;3174,4668;3174,4725;4092,4668;4092,4725;5010,4668;5010,4725;5927,4668;5927,4725;6845,4668;6845,4725;7763,4668;7763,4725;8681,4668;8681,4725;9598,4668;9598,4725;10516,4668;10516,4725"
   o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="AutoShape_x0020_70" o:spid="_x0000_s1028" style='position:absolute;
  top:15650;width:7342;height:520;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="7342,520" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m2715,-11891r919,346l4550,-11502t918,-519l6386,-11631r918,m8221,-12021r918,346l10057,-11675e"
  filled="f" strokecolor="#4f81bd" strokeweight="2pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2715,3759;3634,4105;4550,4148;5468,3629;6386,4019;7304,4019;8221,3629;9139,3975;10057,3975"
   o:connectangles="0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="Picture_x0020_69" o:spid="_x0000_s1029" type="#_x0000_t75"
  style='position:absolute;left:2647;top:3691;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCYSw38vAAAANoAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9LCsIw
EN0L3iGM4EY0VYpoNYoIQhFB/BxgaMa22ExKE229vVkILh/vv952phJvalxpWcF0EoEgzqwuOVdw
vx3GCxDOI2usLJOCDznYbvq9NSbatnyh99XnIoSwS1BB4X2dSOmyggy6ia2JA/ewjUEfYJNL3WAb
wk0lZ1E0lwZLDg0F1rQvKHteX0ZBFqezxcm08ag8H5cPjI+3ZzpXajjodisQnjr/F//cqVYQtoYr
4QbIzRcAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAAAAAAAAAA
W0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAAAAAAAAAA
AAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQCYSw38vAAAANoAAAAPAAAAAAAAAAAA
AAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA8AIAAAAA
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image016.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_68" o:spid="_x0000_s1030" type="#_x0000_t75"
  style='position:absolute;left:3565;top:4037;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image016.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_67" o:spid="_x0000_s1031" type="#_x0000_t75"
  style='position:absolute;left:4483;top:4080;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBmhIb7xAAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/disJA
DIXvBd9hiLA3olOliFZHEWGhyIL48wChE9tiJ1M6s7b79puLhb1LOCfnfNkdBteoN3Wh9mxgMU9A
ERfe1lwaeNw/Z2tQISJbbDyTgR8KcNiPRzvMrO/5Su9bLJWEcMjQQBVjm2kdioochrlviUV7+s5h
lLUrte2wl3DX6GWSrLTDmqWhwpZOFRWv27czUKT5cv3l+nRaX86bJ6bn+ytfGfMxGY5bUJGG+G/+
u86t4Au9/CID6P0vAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAGaEhvvEAAAA2wAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image016.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_66" o:spid="_x0000_s1032" type="#_x0000_t75"
  style='position:absolute;left:5401;top:3560;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image016.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_65" o:spid="_x0000_s1033" type="#_x0000_t75"
  style='position:absolute;left:6317;top:3950;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQD5Gr0XwQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/baoNA
EH0v5B+WCfSl1LUiklg3oRQKIoFSzQcM7kQl7qy422j/vhso9G0O5zrFcTWjuNHsBssKXqIYBHFr
9cCdgnPz8bwD4TyyxtEyKfghB8fD5qHAXNuFv+hW+06EEHY5Kui9n3IpXduTQRfZiThwFzsb9AHO
ndQzLiHcjDKJ40waHDg09DjRe0/ttf42Ctq0THYns6RPw2e1v2BaNdcyU+pxu769gvC0+n/xn7vU
YX4C91/CAfLwCwAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAPkavRfBAAAA2wAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image016.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_64" o:spid="_x0000_s1034" type="#_x0000_t75"
  style='position:absolute;left:7235;top:3950;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image016.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_63" o:spid="_x0000_s1035" type="#_x0000_t75"
  style='position:absolute;left:8153;top:3560;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image016.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_62" o:spid="_x0000_s1036" type="#_x0000_t75"
  style='position:absolute;left:9071;top:3907;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image016.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_61" o:spid="_x0000_s1037" type="#_x0000_t75"
  style='position:absolute;left:9988;top:3907;width:135;height:135;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image016.png"
   o:title=""/>
 </v:shape><v:shape id="AutoShape_x0020_60" o:spid="_x0000_s1038" style='position:absolute;
  top:15520;width:7342;height:1083;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="7342,1083" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m2715,-13191r919,606l4550,-12368t918,-909l6386,-12757r918,216m8221,-13450r918,693l10057,-12585e"
  filled="f" strokecolor="#c0504d" strokeweight="2pt">
  <v:stroke dashstyle="dot"/>
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2715,2329;3634,2935;4550,3152;5468,2243;6386,2763;7304,2979;8221,2070;9139,2763;10057,2935"
   o:connectangles="0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="Picture_x0020_59" o:spid="_x0000_s1039" type="#_x0000_t75"
  style='position:absolute;left:2645;top:2260;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image004.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_58" o:spid="_x0000_s1040" type="#_x0000_t75"
  style='position:absolute;left:3563;top:2866;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image005.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_57" o:spid="_x0000_s1041" type="#_x0000_t75"
  style='position:absolute;left:4481;top:3082;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image002.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_56" o:spid="_x0000_s1042" type="#_x0000_t75"
  style='position:absolute;left:5399;top:2173;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image002.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_55" o:spid="_x0000_s1043" type="#_x0000_t75"
  style='position:absolute;left:6316;top:2692;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image003.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_54" o:spid="_x0000_s1044" type="#_x0000_t75"
  style='position:absolute;left:7234;top:2909;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image002.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_53" o:spid="_x0000_s1045" type="#_x0000_t75"
  style='position:absolute;left:8152;top:2000;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image002.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_52" o:spid="_x0000_s1046" type="#_x0000_t75"
  style='position:absolute;left:9070;top:2692;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image003.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_51" o:spid="_x0000_s1047" type="#_x0000_t75"
  style='position:absolute;left:9986;top:2866;width:139;height:139;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image004.png"
   o:title=""/>
 </v:shape><v:shape id="AutoShape_x0020_50" o:spid="_x0000_s1048" style='position:absolute;
  top:15780;width:7342;height:434;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="7342,434" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m2715,-12888r919,174l4550,-12455t918,-346l6386,-12584r918,129m8221,-12801r918,174l10057,-12455e"
  filled="f" strokecolor="#f79646" strokeweight="2pt">
  <v:stroke dashstyle="dash"/>
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2715,2892;3634,3066;4550,3325;5468,2979;6386,3196;7304,3325;8221,2979;9139,3153;10057,3325"
   o:connectangles="0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="Picture_x0020_49" o:spid="_x0000_s1049" type="#_x0000_t75"
  style='position:absolute;left:2650;top:2827;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image008.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_48" o:spid="_x0000_s1050" type="#_x0000_t75"
  style='position:absolute;left:3568;top:3001;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image007.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_47" o:spid="_x0000_s1051" type="#_x0000_t75"
  style='position:absolute;left:4485;top:3260;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image007.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_46" o:spid="_x0000_s1052" type="#_x0000_t75"
  style='position:absolute;left:5403;top:2913;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image006.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_45" o:spid="_x0000_s1053" type="#_x0000_t75"
  style='position:absolute;left:6321;top:3130;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image009.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_44" o:spid="_x0000_s1054" type="#_x0000_t75"
  style='position:absolute;left:7239;top:3260;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQD4z2e8xQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvQv/D8gredFNFK6mrFGlLFS9NSunxkX0modm3a3aN8d+7gtDjMDPfMMt1bxrRUetrywqexgkI
4sLqmksF3/n7aAHCB2SNjWVScCEP69XDYImptmf+oi4LpYgQ9ikqqEJwqZS+qMigH1tHHL2DbQ2G
KNtS6hbPEW4aOUmSuTRYc1yo0NGmouIvOxkFiesWDg+z/W++/cmayfPx7YN2Sg0f+9cXEIH68B++
tz+1gukUbl/iD5CrKwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQD4z2e8xQAAANsAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image008.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_43" o:spid="_x0000_s1055" type="#_x0000_t75"
  style='position:absolute;left:8155;top:2913;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQD6gpJWwwAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ra8Iw
FIXfhf2HcAd703RORDpTkbENRXzQ+QPumts2rLkpSWbrvzeC4OPhnPMdznI12FacyQfjWMHrJANB
XDptuFZw+vkaL0CEiKyxdUwKLhRgVTyNlphr1/OBzsdYiwThkKOCJsYulzKUDVkME9cRJ69y3mJM
0tdSe+wT3LZymmVzadFwWmiwo4+Gyr/jv1UwXUffm1++mP2Jv3eLbR8+q1qpl+dh/Q4i0hAf4Xt7
oxW8zeD2Jf0AWVwBAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEA+oKSVsMAAADbAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image006.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_42" o:spid="_x0000_s1056" type="#_x0000_t75"
  style='position:absolute;left:9073;top:3087;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image007.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_41" o:spid="_x0000_s1057" type="#_x0000_t75"
  style='position:absolute;left:9991;top:3260;width:130;height:130;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image008.png"
   o:title=""/>
 </v:shape><v:line id="Line_x0020_40" o:spid="_x0000_s1058" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="3365,763" to="3869,763"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokecolor="#4f81bd" strokeweight="2pt"/>
 <v:shape id="Picture_x0020_39" o:spid="_x0000_s1059" type="#_x0000_t75"
  style='position:absolute;left:3560;top:706;width:114;height:114;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image017.png"
   o:title=""/>
 </v:shape><v:line id="Line_x0020_38" o:spid="_x0000_s1060" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="5631,763" to="6135,763"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQB5pcpMxgAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9BawIx
FITvBf9DeIVeipu1QmlXo5RqsXiQdvXg8bF5Jls3L8sm1bW/3hQKPQ4z8w0znfeuESfqQu1ZwSjL
QRBXXtdsFOy2b8MnECEia2w8k4ILBZjPBjdTLLQ/8yedymhEgnAoUIGNsS2kDJUlhyHzLXHyDr5z
GJPsjNQdnhPcNfIhzx+lw5rTgsWWXi1Vx/LbKTBfF728L/eMH71Zjcr1z0bahVJ3t/3LBESkPv6H
/9rvWsH4GX6/pB8gZ1cAAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAA
CwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAeaXKTMYAAADbAAAA
DwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPoCAAAAAA==
" strokecolor="#c0504d" strokeweight="2pt">
  <v:stroke dashstyle="dot"/>
 </v:line><v:shape id="Picture_x0020_37" o:spid="_x0000_s1061" type="#_x0000_t75"
  style='position:absolute;left:5813;top:693;width:139;height:139;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image005.png"
   o:title=""/>
 </v:shape><v:line id="Line_x0020_36" o:spid="_x0000_s1062" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="7983,763" to="8487,763"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokecolor="#f79646" strokeweight="2pt">
  <v:stroke dashstyle="dash"/>
 </v:line><v:shape id="Picture_x0020_35" o:spid="_x0000_s1063" type="#_x0000_t75"
  style='position:absolute;left:8179;top:706;width:110;height:110;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image018.png"
   o:title=""/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="553" height="269" src="file:///C:/Users/hmc103/AppData/Local/Packages/oice_16_974fa576_32c1d314_1dac/AC/Temp/msohtmlclip1/01/clip_image019.gif" /><strong>Figure 2: Study 302 mean IOP (mmHg) by treatment group and treatment difference in mean IOP</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:648px"><tbody><tr><td colspan="10" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Roclanda&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Netarsudil&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Latanoprost</p><p><strong>&nbsp;</strong></p><p>22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Baseline&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Baseline&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Baseline</p><p>8AM&nbsp; &nbsp;10AM&nbsp; &nbsp;4PM&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8AM&nbsp; &nbsp;10AM&nbsp; &nbsp;4PM&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8AM&nbsp;&nbsp;&nbsp; 10AM&nbsp; &nbsp;4PM</p><p>21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22.6</p><p><strong>&nbsp;</strong></p><p>20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20.0</p><p>19.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19.6</p><p>19</p><p>18.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18.4</p><p>18.1</p><p>18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18.0</p><p>17.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.5</p><p>17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.1</p><p>16.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16.4</p><p>16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16.1</p><p>15.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15.6</p><p>15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15.6</p><p>14</p><p>Day 15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 90 (8AM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (10AM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (4PM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (8AM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (10AM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (4PM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (8AM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (10AM)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (4PM)</p></td></tr><tr><td style="vertical-align:top"><p><strong>latanoprost + netarsudil vs. netarsudil</strong></p><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p><strong>3.4</strong></p><p><strong>&nbsp;</strong></p><p><strong>(2.8, 3.9)</strong></p></td><td style="vertical-align:top"><p><strong>2.7</strong></p><p><strong>&nbsp;</strong></p><p><strong>(2.2, 3.2)</strong></p></td><td style="vertical-align:top"><p><strong>2.2</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.7, 2.8)</strong></p></td><td style="vertical-align:top"><p><strong>3.2</strong></p><p><strong>&nbsp;</strong></p><p><strong>(2.6, 3.8)</strong></p></td><td style="vertical-align:top"><p><strong>2.9</strong></p><p><strong>&nbsp;</strong></p><p><strong>(2.3, 3.4)</strong></p></td><td style="vertical-align:top"><p><strong>2.3</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.8, 2.9)</strong></p></td><td style="vertical-align:top"><p><strong>3.6</strong></p><p><strong>&nbsp;</strong></p><p><strong>(3.0, 4.2)</strong></p></td><td style="vertical-align:top"><p><strong>2.8</strong></p><p><strong>&nbsp;</strong></p><p><strong>(2.3, 3.4)</strong></p></td><td style="vertical-align:top"><p><strong>2.4</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.9, 2.9)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>latanoprost + netarsudil vs. latanoprost</strong></p><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p><strong>2.0</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.5, 2.6)</strong></p></td><td style="vertical-align:top"><p><strong>2.4</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.9, 2.9)</strong></p></td><td style="vertical-align:top"><p><strong>1.9</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.3, 2.4)</strong></p></td><td style="vertical-align:top"><p><strong>1.5</strong></p><p><strong>&nbsp;</strong></p><p><strong>(0.9, 2.1)</strong></p></td><td style="vertical-align:top"><p><strong>1.9</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.3, 2.4)</strong></p></td><td style="vertical-align:top"><p><strong>1.6</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.0, 2.1)</strong></p></td><td style="vertical-align:top"><p><strong>1.5</strong></p><p><strong>&nbsp;</strong></p><p><strong>(0.9, 2.2)</strong></p></td><td style="vertical-align:top"><p><strong>2.0</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.4, 2.5)</strong></p></td><td style="vertical-align:top"><p><strong>1.5</strong></p><p><strong>&nbsp;</strong></p><p><strong>(1.0, 2.1)</strong></p></td></tr></tbody></table><p>The LS mean IOP at each post-baseline time point was derived using an analysis of covariance adjusted for baseline IOP and based on observed data for all randomized subjects (245 in latanoprost + netarsudil group, 255 in netarsudil group, 250 in latanoprost group).</p><p>&nbsp;</p><p>Approximately 67% of subjects included in the latanoprost + netarsudil treatment groups of Phase 3 studies were caucasian and 30% black or african american. Over half were aged &ge; 65 years. With the exception of the incidence of cornea verticillata (section 4.8); no other difference in safety profile was observed between races or age groups.</p><p>&nbsp;</p><p>Completion rates in studies 301 and 302 were lower in the latanoprost + netarsudil treatment groups when compared with the latanoprost group. Discontinuation rates due to adverse events at month 3 were 8.7% for the pooled latanoprost + netarsudil treatment group versus 7.6% for the pooled netarsudil group and 1.0% for the pooled latanoprost group. Discontinuation rates due to adverse events at month 12 in Study 301 were 19.7% for the latanoprost + netarsudil treatment group versus 21.7% for the netarsudil group and 1.7% for the latanoprost group. The majority of discontinuations were associated with ocular events. The most frequently reported adverse event associated with discontinuation in the latanoprost + netarsudil group was conjunctival hyperemia (7.6% at month 12). The majority of ocular adverse events reported with netarsudil + latanoprost were mild in intensity.</p><p>&nbsp;</p><p>Study 303 was a prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of latanoprost + netarsudil compared to bimatoprost + timolol in 430 subjects with elevated intraocular pressure. Subjects were randomly assigned to a planned fixed-dose treatment regimen with latanoprost + netarsudil one drop (218 subjects), once daily (QD) each evening in both eyes (OU) or comparator bimatoprost + timolol (212 subjects) one drop QD each evening OU for approximately 180 days following a washout period.</p><p>&nbsp;</p><p>The primary efficacy outcome was the comparison of latanoprost + netarsudil to bimatoprost + timolol for Mean IOP at specified timepoints at Week 2, Week 6, and Month 3. The primary analysis was performed on the ITT population with imputation by Markov Chain Monte Carlo (MCMC) method. This analysis demonstrated clinical non-inferiority of latanoprost + netarsudil ophthalmic solution relative to bimatoprost + timolol dosed QD in the ITT population with the upper limit of the 95% CIs around the difference (latanoprost + netarsudil - bimatoprost + timolol) &le; 1.5 mmHg at all 9 time points and &le; 1.0 mmHg at the majority (6 out of 9) of time points from Week 2 through Month 3, meeting the criteria for success. The threshold for clinical non-inferiority of latanoprost + netarsudil QD relative to bimatoprost + timolol QD (the between-group difference &le; 1.5 mmHg) was demonstrated in the PP population at 8 out of 9 time points (08:00, 10.00, and 16:00) at week 2, through month 3 using the MCMC method. However, clinical non inferiority was not met overall since at the week 6 08:00 time point, the upper bound 95% CI was 1.55. Overall, there was a similar mean IOP reduction throughout the day of approximately 9.5 mmHg between both the latanoprost + netarsudil and bimatoprost + timolol treatment group.</p><p>&nbsp;</p><p>The overall rate of discontinuation from the study treatment due to a TEAE was 11.2%. More subjects in the latanoprost + netarsudil QD treatment group&nbsp;&nbsp; discontinued from the study treatment due to a TEAE (20.2%) compared to&nbsp; the bimatoprost + timolol QD group (1.9%), and the majority of TEAEs leading to discontinuation were ocular TEAEs. No serious treatment-related adverse events were reported in any treatment group, and the safety profile remains consistent with the known profile for latanoprost + netarsudil, and/or latanoprost or netarsudil alone.</p><p>&nbsp;</p><p>The efficacy and safety of latanoprost + netarsudil in subjects with compromised corneal epithelium or co-existing ocular pathologies e.g. pseudoexfoliation and dispersion pigment syndrome has not been established.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Roclanda in all subsets of the paediatric population for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>The systemic exposures of netarsudil and its active metabolite, AR-13503, were evaluated in</p><p>18 healthy subjects after topical ocular administration of netarsudil 200 micrograms/ml once daily (one drop bilaterally in the morning) for 8 days. There were no quantifiable plasma concentrations of netarsudil (lower limit of quantitation (LLOQ) 0.100 ng/ml) post dose on Day 1 and Day 8. Only one plasma concentration at 0.11 ng/ml for the active metabolite was observed for one subject on Day 8 at 8 hours post-dose.</p><p>&nbsp;</p><p>Latanoprost (molecular weight 432.58) is an isopropyl ester prodrug which per se is inactive, but after hydrolysis to the acid of latanoprost becomes biologically active. The prodrug is well absorbed through the cornea and all active substance that enters the aqueous humour is hydrolysed during the passage through the cornea. Studies in man indicate that the peak concentration in the aqueous humour is reached about two hours after topical administration. After topical application in monkeys, latanoprost is distributed primarily in the anterior segment, the conjunctivae and the eyelids. Only minute quantities of latanoprost reach the posterior segment.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>After topical ocular dosing, netarsudil is metabolized by esterases in the eye to an active metabolite, AR-13503.</p><p>&nbsp;</p><p>There is practically no metabolism of the acid of latanoprost in the eye. The main metabolism occurs in the liver. The half-life in plasma is 17 minutes in man. The main metabolites, the 1,2-dinor and 1,2,3,4-tetranor metabolites, exert no or only weak biological activity in animal studies and are excreted primarily in the urine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Netarsudil</u></p><p>&nbsp;</p><p>Non-clinical data with netarsudil reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to development. Effects in</p><p>non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.</p><p>&nbsp;</p><p>Intravenous administration of netarsudil to pregnant rats and rabbits during organogenesis did not produce adverse embryofetal effects at clinically relevant systemic exposures. In pregnant rats,</p><p>0.1 mg/kg/day showed no adverse maternal or embryofoetal effects, whereas increased</p><p>post-implantation loss and reduced foetal viability was observed at 0.3 mg/kg/day and higher.</p><p>In pregnant rabbits, 3 mg/kg/day showed no maternal or embryofoetal effects, whereas an increase in post-implantation loss and a decrease in foetal weight were observed at 5 mg/kg/day.</p><p>&nbsp;</p><p>Long-term studies in animals have not been performed to evaluate the carcinogenic potential of netarsudil.</p><p>&nbsp;</p><p>Netarsudil was not mutagenic in a bacterial mutation assay, in a mouse lymphoma assay, or in a rat micronucleus test.</p><p>&nbsp;</p><p>Netarsudil and its active metabolite AR-13503 was found to have a possible phototoxic potential in a modified 3T3 NRU-PT <em>in vitro </em>assay, where the wavelength was extended to include UVB light.</p><p><u>Latanoprost</u></p><p>&nbsp;</p><p>The ocular as well as systemic toxicity of latanoprost has been investigated in several animal species. Generally, latanoprost is well tolerated with a safety margin between clinical ocular dose and systemic toxicity of at least 1000 times. High doses of latanoprost, approximately 100 times the clinical dose/kg body weight, administered intravenously to unanaesthetised monkeys have been shown to increase the respiration rate probably reflecting bronchoconstriction of short duration. In animal studies, latanoprost has not been found to have sensitising properties.</p><p>&nbsp;</p><p>In the eye, no toxic effects have been detected with doses of up to 100 micrograms/eye/day in rabbits or monkeys (clinical dose is approximately 1.5 micrograms/eye/day). In monkeys, however, latanoprost has been shown to induce increased pigmentation of the iris. The mechanism of increased pigmentation seems to be stimulation of melanin production in melanocytes of the iris with no proliferative changes observed. The change in iris colour may be permanent.</p><p>&nbsp;</p><p>In chronic ocular toxicity studies, administration of latanoprost 6 micrograms/eye/day has also been shown to induce increased palpebral fissure. This effect is reversible and occurs at doses above the clinical dose level. The effect has not been seen in humans.</p><p>&nbsp;</p><p>Latanoprost was found negative in reverse mutation tests in bacteria, gene mutation in mouse lymphoma and mouse micronucleus test. Chromosome aberrations were observed <em>in vitro </em>with human lymphocytes. Similar effects were observed with prostaglandin F2&alpha;, a naturally occurring prostaglandin, and indicates that this is a class effect.</p><p>&nbsp;</p><p>Additional mutagenicity studies on <em>in vitro</em>/<em>in vivo </em>unscheduled DNA synthesis in rats were negative and indicate that latanoprost does not have mutagenic potency. Carcinogenicity studies in mice and rats were negative.</p><p>&nbsp;</p><p>Latanoprost has not been found to have any effect on male or female fertility in animal studies. In the embryotoxicity study in rats, no embryotoxicity was observed at intravenous doses (5, 50 and</p><p>250 micrograms/kg/day) of latanoprost. However, latanoprost induced embryolethal effects in rabbits at doses of 5 micrograms/kg/day and above.</p><p>&nbsp;</p><p>The dose of 5 micrograms/kg/day (approximately 100 times the clinical dose) caused significant embryofoetal toxicity characterised by increased incidence of late resorption and abortion and by reduced foetal weight.</p><p>&nbsp;</p><p>No teratogenic potential has been detected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Benzalkonium chloride</p><p>Mannitol</p><p>Boric acid</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
After first opening: to be used within 4 weeks. Do not store above 25 °C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2 &deg;C &ndash; 8 &deg;C). Store in the original carton in order to protect from light. For storage conditions after first opening of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Roclanda is supplied in clear low density polyethylene bottles (2.5 ml fill in a 4 ml container), opaque white low density polyethylene tips with opaque white polypropylene screw caps and anti-tamper seals.</p><p>&nbsp;</p><p>Pack size: 1 bottle x 2.5&nbsp;ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Santen Oy
Tampere, Finland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>